184 related articles for article (PubMed ID: 36465803)
1. Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag.
Hinkamp C; Bartolome S; Mims E; Chin K; Shah T
Biomed Hub; 2022; 7(3):115-124. PubMed ID: 36465803
[TBL] [Abstract][Full Text] [Related]
2. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
[TBL] [Abstract][Full Text] [Related]
3. Selexipag for the Treatment of Pediatric Pulmonary Hypertension: A Systematic Review.
Li M; Liu L; Liu C; Chen Z; Li W; Li X; Ma X; Zhang Y
Clin Ther; 2024 Jan; 46(1):59-68. PubMed ID: 37945502
[TBL] [Abstract][Full Text] [Related]
4. Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension.
Pan IZ; Carey JR; Jacobs JA; Dechand J; Sessions JJ; Sorensen T; Penn BA; Mayeux JD; Hatton ND; Ryan JJ
Front Med (Lausanne); 2020; 7():81. PubMed ID: 32296704
[No Abstract] [Full Text] [Related]
5. An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertension.
Oudiz R; Agarwal M; Rischard F; De Marco T
Pulm Circ; 2016 Dec; 6(4):532-538. PubMed ID: 28090295
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension.
Colglazier E; Stevens L; Parker C; Nawaytou HM; Amin EK; Becerra J; Steurer M; Fineman JR
Pulm Circ; 2022 Oct; 12(4):e12159. PubMed ID: 36514390
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
8. Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Hinkamp CA; Shah T; Bartolome S; Torres F; Chin KM
J Thorac Dis; 2021 Mar; 13(3):1466-1475. PubMed ID: 33841939
[TBL] [Abstract][Full Text] [Related]
9. Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine.
Douwes JM; Zijlstra WMH; Rosenzweig EB; Ploegstra MJ; Krishnan US; Haarman MG; Roofthooft MTR; Postmus D; Hillege HL; Ivy DD; Berger RMF
Ann Am Thorac Soc; 2022 Feb; 19(2):227-237. PubMed ID: 34181866
[No Abstract] [Full Text] [Related]
10. Prostacyclin for pulmonary arterial hypertension.
Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
[TBL] [Abstract][Full Text] [Related]
11. Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients.
Cui X; Lu W; Zhang D; Qie L; Li H; Li X; Liu H; Ji Q
Front Cardiovasc Med; 2022; 9():991586. PubMed ID: 36204579
[TBL] [Abstract][Full Text] [Related]
12. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
[TBL] [Abstract][Full Text] [Related]
13. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
[TBL] [Abstract][Full Text] [Related]
14. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
Chakinala MM; Feldman JP; Rischard F; Mathier M; Broderick M; Leedom N; Laliberte K; White RJ
J Heart Lung Transplant; 2017 Feb; 36(2):193-201. PubMed ID: 27469018
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost.
Channick RN; Frantz RP; Kawut SM; Palevsky H; Tumuluri R; Sulica R; Lauto PO; Benton WW; de Boisblanc B
Pulm Circ; 2013 Apr; 3(2):381-8. PubMed ID: 24015339
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension.
Tamura Y; Furukawa A; Tamura Y; Yamada K; Taniguchi H; Fukuda K; Kawamura A; Satoh T
Pulm Circ; 2022 Jan; 12(1):e12058. PubMed ID: 35506073
[TBL] [Abstract][Full Text] [Related]
17. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
Verlinden NJ; Walter C; Raina A; Benza RL
J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036
[TBL] [Abstract][Full Text] [Related]
18. Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: A systematic review and meta-analysis.
Wang S; Yan Y; Zhang J; Yuan P; Luo CJ; Qiu HL; Li HT; Xu J; Wang L; Li TL; Jiang R
Animal Model Exp Med; 2024 Feb; 7(1):56-70. PubMed ID: 37740617
[TBL] [Abstract][Full Text] [Related]
19. Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension.
Diaz-Guzman E; Heresi GA; Dweik RA; Minai OA
Respir Med; 2008 May; 102(5):681-9. PubMed ID: 18280130
[TBL] [Abstract][Full Text] [Related]
20. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy.
Adachi S; Nishiyama I; Yasuda K; Yoshida M; Nakano Y; Kondo T; Murohara T
J Cardiol Cases; 2022 Jul; 26(1):42-45. PubMed ID: 35923524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
